Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174977 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics Distribution of Raltegravir by PET/MR
A Early Phase 1 study of HIV-1-infection, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03174977: Recruiting Early Phase 1 study of HIV-1-infection, sponsored by University of California, San Francisco.
NCT03174977 is a Early Phase 1 study of HIV-1-infection that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03174977, a Early Phase 1 study of HIV-1-infection, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order to determine the distribution of radiolabeled drug through the lymphoreticular system and other tissues throughout the entire body.
Conditions Studied
Interventions
- DRUG 18F-Raltegravir
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2025-01-01 |
| Phase | Early Phase 1 |
What NCT03174977 shows while recruiting
NCT03174977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which 18F-Raltegravir is the first listed.
NCT03174977 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03174977 about?
NCT03174977 is a clinical study titled "Pharmacokinetics Distribution of Raltegravir by PET/MR". This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order ...
What is the current status of trial NCT03174977?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-04-01. Estimated completion is 2025-01-01.
What conditions does trial NCT03174977 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT03174977?
The interventions under investigation include: 18F-Raltegravir (DRUG).
Who is sponsoring clinical trial NCT03174977?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03174977 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03174977's enrollment target sits among peer trials
10 71st of 71 higher than 1 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
RECRUITING · Early Phase 1
-
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
ACTIVE NOT RECRUITING · Early Phase 1
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI